Clover Health officer sells $1.4M in stock

Clover Health officer Wai Conrad sold 300,000 Class A shares under a pre-set Rule 10b5-1 plan and continues to hold over 2.2 million shares directly and through a family trust.

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) reports that officer Wai Conrad, CEO of Counterpart Health, filed a Form 4 disclosing the sale of 300,000 shares of Class A common stock on September 15, 2026. The sale was executed at a weighted average price of $4.72 per share under a Rule 10b5-1 trading plan adopted on June 8, 2026, with individual trade prices ranging from $4.60 to $5.06. The shares sold were held indirectly in a family trust for which he serves as co-trustee; after the sale, that trust held 1,170,056 shares, and he also reported 1,065,699 shares held directly.

Insider Trade Summary 10b5-1

Net Seller: 300,000 shares

Net Sell 2 txns

Insider Wai Conrad

Role CEO, Counterpart Health

Sold 300,000 shs ($1.42M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	300,000	$4.72	$1.42M
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,170,056 shares (Indirect, By Trust.); Class A Common Stock — 1,065,699 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.60 to $5.06, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. F2. Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.

Key Figures

Shares sold: 300,000 shares Weighted average sale price: $4.72 per share Approximate sale proceeds: $1.42 million +4 more

7 metrics

Shares sold 300,000 shares Class A common stock sold on September 15, 2026 by Wai Conrad

Weighted average sale price $4.72 per share Average price for the 300,000 shares sold on September 15, 2026

Approximate sale proceeds $1.42 million Estimated value of 300,000 shares sold at a weighted average of $4.72

Indirect holdings after sale 1,170,056 shares Class A shares held in a family trust after the reported sale

Direct holdings after transactions 1,065,699 shares Class A shares reported as directly owned after the filing’s transactions

Trade price range $4.60–$5.06 per share Range of prices for individual trades making up the reported sale

Rule 10b5-1 plan adoption date June 8, 2026 Date on which the trading plan governing the sale was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, co-trustee

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

co-trustee financial

"Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CLOV report for Wai Conrad on September 15, 2026?

Clover Health reported that officer Wai Conrad sold 300,000 shares of Class A common stock on September 15, 2026 at a weighted average price of $4.72 per share through an arranged trading plan.

Was the CLOV insider sale by Wai Conrad made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Wai Conrad on June 8, 2026, indicating the trades were pre-arranged rather than timed discretionarily.

What price range did Wai Conrad receive for the CLOV shares sold?

The filing reports a weighted average price of $4.72 per share and notes that the 300,000 shares were sold in multiple transactions at prices ranging from $4.60 to $5.06, inclusive.

How many CLOV shares does Wai Conrad hold indirectly after the reported sale?

After the reported sale, a family trust associated with Wai Conrad held 1,170,056 shares of Clover Health Class A common stock. The filing notes the shares are held in trust for his family, with him serving as co-trustee.

How many CLOV shares does Wai Conrad hold directly after this Form 4 filing?

The Form 4 shows a separate line for direct ownership indicating that Wai Conrad held 1,065,699 shares of Clover Health Class A common stock directly after the reported transactions and positions.

What is the approximate dollar value of Wai Conrad’s CLOV share sale?

Multiplying the 300,000 shares sold by the $4.72 weighted average price gives an approximate transaction value of about $1.42 million, based on the figures provided in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:27 PM Accepted by SEC EDGAR 09/16/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wai Conrad

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Counterpart Health

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/15/2026		S		300,000(1)	D	$4.72	1,170,056	I	By Trust.(2)
Class A Common Stock								1,065,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.60 to $5.06, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.

Remarks:

	/s/ Peter J. Rivas as attorney-in-fact for Conrad Wai	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)